Hepatitis C virus infection in Argentina: Burden of chronic disease
- Autores
- Ridruejo, Ezequiel; Bessone, Fernando; Daruich, Jorge R.; Estes, Chris; Gadano, Adrián Carlos; Razavi, Homie; Villamil, Federico; Silva, Marcelo Oscar
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- AIM: To estimate the progression of the hepatitis C virus (HCV) epidemic and measure the burden of HCVrelated morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population in Argentina and estimate HCV incidence, prevalence, hepatic complications, and mortality. The relative impact of two scenarios on HCV-related outcomes was assessed: (1) increased sustained virologic response (SVR); and (2) increased SVR and treatment. RESULTS: Under scenario 1, SVR raised to 85%-95% in 2016. Compared to the base case scenario, there was a 0.3% reduction in prevalent cases and liverrelated deaths by 2030. Given low treatment rates, cases of hepatocellular carcinoma and decompensated cirrhosis decreased < 1%, in contrast to the base case in 2030. Under scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations. This scenario decreased prevalent infections 45%, liver-related deaths 55%, liver cancer cases 60%, and decompensated cirrhosis 55%, as compared to the base case by 2030. CONCLUSION: In Argentina, cases of end stage liver disease and liver-related deaths due to HCV are still growing, while its prevalence is decreasing. Increasing in SVR rates is not enough, and increasing in the number of patients diagnosed and candidates for treatment is needed to reduce the HCV disease burden. Based on this scenario, strategies to increase diagnosis and treatment uptake must be developed to reduce HCV burden in Argentina.
Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Austral. Hospital Universitario Austral.; Argentina. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; Argentina
Fil: Bessone, Fernando. Universidad Nacional de Rosario; Argentina
Fil: Daruich, Jorge R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Estes, Chris. Center For Disease Analysis; Estados Unidos
Fil: Gadano, Adrián Carlos. Hospital Italiano; Argentina
Fil: Razavi, Homie. Center For Disease Analysis; Estados Unidos
Fil: Villamil, Federico. Hospital Británico de Buenos Aires; Argentina
Fil: Silva, Marcelo Oscar. Universidad Austral. Hospital Universitario Austral.; Argentina - Materia
-
ARGENTINA
DIAGNOSIS
DISEASE BURDEN
EPIDEMIOLOGY
HEPATITIS C
INCIDENCE
MORTALITY
PREVALENCE
TREATMENT - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/105873
Ver los metadatos del registro completo
id |
CONICETDig_de65973e104e7614ab57d3e704f9915b |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/105873 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Hepatitis C virus infection in Argentina: Burden of chronic diseaseRidruejo, EzequielBessone, FernandoDaruich, Jorge R.Estes, ChrisGadano, Adrián CarlosRazavi, HomieVillamil, FedericoSilva, Marcelo OscarARGENTINADIAGNOSISDISEASE BURDENEPIDEMIOLOGYHEPATITIS CINCIDENCEMORTALITYPREVALENCETREATMENThttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3AIM: To estimate the progression of the hepatitis C virus (HCV) epidemic and measure the burden of HCVrelated morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population in Argentina and estimate HCV incidence, prevalence, hepatic complications, and mortality. The relative impact of two scenarios on HCV-related outcomes was assessed: (1) increased sustained virologic response (SVR); and (2) increased SVR and treatment. RESULTS: Under scenario 1, SVR raised to 85%-95% in 2016. Compared to the base case scenario, there was a 0.3% reduction in prevalent cases and liverrelated deaths by 2030. Given low treatment rates, cases of hepatocellular carcinoma and decompensated cirrhosis decreased < 1%, in contrast to the base case in 2030. Under scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations. This scenario decreased prevalent infections 45%, liver-related deaths 55%, liver cancer cases 60%, and decompensated cirrhosis 55%, as compared to the base case by 2030. CONCLUSION: In Argentina, cases of end stage liver disease and liver-related deaths due to HCV are still growing, while its prevalence is decreasing. Increasing in SVR rates is not enough, and increasing in the number of patients diagnosed and candidates for treatment is needed to reduce the HCV disease burden. Based on this scenario, strategies to increase diagnosis and treatment uptake must be developed to reduce HCV burden in Argentina.Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Austral. Hospital Universitario Austral.; Argentina. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; ArgentinaFil: Bessone, Fernando. Universidad Nacional de Rosario; ArgentinaFil: Daruich, Jorge R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Estes, Chris. Center For Disease Analysis; Estados UnidosFil: Gadano, Adrián Carlos. Hospital Italiano; ArgentinaFil: Razavi, Homie. Center For Disease Analysis; Estados UnidosFil: Villamil, Federico. Hospital Británico de Buenos Aires; ArgentinaFil: Silva, Marcelo Oscar. Universidad Austral. Hospital Universitario Austral.; ArgentinaBaishideng Publishing Group2016-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/105873Ridruejo, Ezequiel; Bessone, Fernando; Daruich, Jorge R.; Estes, Chris; Gadano, Adrián Carlos; et al.; Hepatitis C virus infection in Argentina: Burden of chronic disease; Baishideng Publishing Group; World Journal of Hepatology; 8; 15; 5-2016; 649-6581948-5182CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4254/wjh.v8.i15.649info:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/1948-5182/full/v8/i15/649.htminfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:34:52Zoai:ri.conicet.gov.ar:11336/105873instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:34:52.749CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Hepatitis C virus infection in Argentina: Burden of chronic disease |
title |
Hepatitis C virus infection in Argentina: Burden of chronic disease |
spellingShingle |
Hepatitis C virus infection in Argentina: Burden of chronic disease Ridruejo, Ezequiel ARGENTINA DIAGNOSIS DISEASE BURDEN EPIDEMIOLOGY HEPATITIS C INCIDENCE MORTALITY PREVALENCE TREATMENT |
title_short |
Hepatitis C virus infection in Argentina: Burden of chronic disease |
title_full |
Hepatitis C virus infection in Argentina: Burden of chronic disease |
title_fullStr |
Hepatitis C virus infection in Argentina: Burden of chronic disease |
title_full_unstemmed |
Hepatitis C virus infection in Argentina: Burden of chronic disease |
title_sort |
Hepatitis C virus infection in Argentina: Burden of chronic disease |
dc.creator.none.fl_str_mv |
Ridruejo, Ezequiel Bessone, Fernando Daruich, Jorge R. Estes, Chris Gadano, Adrián Carlos Razavi, Homie Villamil, Federico Silva, Marcelo Oscar |
author |
Ridruejo, Ezequiel |
author_facet |
Ridruejo, Ezequiel Bessone, Fernando Daruich, Jorge R. Estes, Chris Gadano, Adrián Carlos Razavi, Homie Villamil, Federico Silva, Marcelo Oscar |
author_role |
author |
author2 |
Bessone, Fernando Daruich, Jorge R. Estes, Chris Gadano, Adrián Carlos Razavi, Homie Villamil, Federico Silva, Marcelo Oscar |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
ARGENTINA DIAGNOSIS DISEASE BURDEN EPIDEMIOLOGY HEPATITIS C INCIDENCE MORTALITY PREVALENCE TREATMENT |
topic |
ARGENTINA DIAGNOSIS DISEASE BURDEN EPIDEMIOLOGY HEPATITIS C INCIDENCE MORTALITY PREVALENCE TREATMENT |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
AIM: To estimate the progression of the hepatitis C virus (HCV) epidemic and measure the burden of HCVrelated morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population in Argentina and estimate HCV incidence, prevalence, hepatic complications, and mortality. The relative impact of two scenarios on HCV-related outcomes was assessed: (1) increased sustained virologic response (SVR); and (2) increased SVR and treatment. RESULTS: Under scenario 1, SVR raised to 85%-95% in 2016. Compared to the base case scenario, there was a 0.3% reduction in prevalent cases and liverrelated deaths by 2030. Given low treatment rates, cases of hepatocellular carcinoma and decompensated cirrhosis decreased < 1%, in contrast to the base case in 2030. Under scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations. This scenario decreased prevalent infections 45%, liver-related deaths 55%, liver cancer cases 60%, and decompensated cirrhosis 55%, as compared to the base case by 2030. CONCLUSION: In Argentina, cases of end stage liver disease and liver-related deaths due to HCV are still growing, while its prevalence is decreasing. Increasing in SVR rates is not enough, and increasing in the number of patients diagnosed and candidates for treatment is needed to reduce the HCV disease burden. Based on this scenario, strategies to increase diagnosis and treatment uptake must be developed to reduce HCV burden in Argentina. Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Austral. Hospital Universitario Austral.; Argentina. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; Argentina Fil: Bessone, Fernando. Universidad Nacional de Rosario; Argentina Fil: Daruich, Jorge R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina Fil: Estes, Chris. Center For Disease Analysis; Estados Unidos Fil: Gadano, Adrián Carlos. Hospital Italiano; Argentina Fil: Razavi, Homie. Center For Disease Analysis; Estados Unidos Fil: Villamil, Federico. Hospital Británico de Buenos Aires; Argentina Fil: Silva, Marcelo Oscar. Universidad Austral. Hospital Universitario Austral.; Argentina |
description |
AIM: To estimate the progression of the hepatitis C virus (HCV) epidemic and measure the burden of HCVrelated morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population in Argentina and estimate HCV incidence, prevalence, hepatic complications, and mortality. The relative impact of two scenarios on HCV-related outcomes was assessed: (1) increased sustained virologic response (SVR); and (2) increased SVR and treatment. RESULTS: Under scenario 1, SVR raised to 85%-95% in 2016. Compared to the base case scenario, there was a 0.3% reduction in prevalent cases and liverrelated deaths by 2030. Given low treatment rates, cases of hepatocellular carcinoma and decompensated cirrhosis decreased < 1%, in contrast to the base case in 2030. Under scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations. This scenario decreased prevalent infections 45%, liver-related deaths 55%, liver cancer cases 60%, and decompensated cirrhosis 55%, as compared to the base case by 2030. CONCLUSION: In Argentina, cases of end stage liver disease and liver-related deaths due to HCV are still growing, while its prevalence is decreasing. Increasing in SVR rates is not enough, and increasing in the number of patients diagnosed and candidates for treatment is needed to reduce the HCV disease burden. Based on this scenario, strategies to increase diagnosis and treatment uptake must be developed to reduce HCV burden in Argentina. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-05 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/105873 Ridruejo, Ezequiel; Bessone, Fernando; Daruich, Jorge R.; Estes, Chris; Gadano, Adrián Carlos; et al.; Hepatitis C virus infection in Argentina: Burden of chronic disease; Baishideng Publishing Group; World Journal of Hepatology; 8; 15; 5-2016; 649-658 1948-5182 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/105873 |
identifier_str_mv |
Ridruejo, Ezequiel; Bessone, Fernando; Daruich, Jorge R.; Estes, Chris; Gadano, Adrián Carlos; et al.; Hepatitis C virus infection in Argentina: Burden of chronic disease; Baishideng Publishing Group; World Journal of Hepatology; 8; 15; 5-2016; 649-658 1948-5182 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.4254/wjh.v8.i15.649 info:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/1948-5182/full/v8/i15/649.htm |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Baishideng Publishing Group |
publisher.none.fl_str_mv |
Baishideng Publishing Group |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613081549766656 |
score |
13.070432 |